Paving the way for a future without alzheimer’s disease

October 4, 2017

The Importance of Clinical Studies

There has been much interest surrounding lifestyle changes to help safeguard against Alzheimer’s disease - diet, physical and mental exercise, social interaction and sleep have all been scientifically proven to have a positive impact on helping to protect against cognitive decline. However, if individuals are at risk or showing signs of cognitive decline, it’s imperative to seek an early diagnosis to ensure access to the very best treatment programme.

Re:Cognition Health, a leading centre for international final phase clinical trials, is changing the future for those with memory loss and other symptoms of cognitive impairment through providing education, clinical excellence and access to the most advanced treatments available, worldwide.

It is an exciting time for research into Alzheimer’s disease and other causes of mild cognitive impairment (MCI) and dementia. Results from clinical trials are always encouraging, bringing us ever closer to treatments to slow down or, ideally, halt the progression of the disease and to improve its symptoms.

Involvement in clinical trials enables individuals to receive the next generation emerging medications, free of charge, before these medications are licensed for global use. Participants receive outstanding medical care and are monitored regularly throughout the study by a team of cognitive experts. All medical costs are covered by the pharmaceutical company, so the very best care and medical facilities are provided at no cost to the individual.

Why clinical trials?

Clinical trials are essential for advancing our understanding of medicine and improving the healthcare and quality of life for everyone affected by dementia and cognitive impairment. By participating in an international clinical study, individuals can gain the potential personal benefit of early access to a new treatment, whilst also having an important global impact on our ability to treat a given condition.

Dr Emer MacSweeney, CEO and Medical Director of Re:Cognition Health comments: “With the introduction of new biomarkers to detect evidence of Alzheimer’s disease at its earliest stage, there is reason for cautious optimism that new generation medications will delay progression of disease and also boost cognition. Just as research through clinical studies has improved our outlook for numerous diseases including previously fatal infections and certain forms of cancer; the same action is being taken today for Alzheimer’s disease. With every study conducted we understand more about the disease and become closer to finding treatments, and ultimately a cure”.

Re:Cognition Health is proud of the pioneering work being undertaken by the consultants and cognitive experts at the clinic and continues to work hard to become one of the most successful clinics in the world for enrolling individuals onto final phase international clinical trials for Alzheimer’s Disease.

Peter Brabner, whose wife Helen was diagnosed with Alzheimer’s disease at the age of 73, is supporting her through the clinical study and is delighted to be part of a potentially life- changing study. He comments: “If someone has a diagnosis of Alzheimer’s Disease I would say get in touch with Re:Cognition Health: they are doing excellent work and look after you so well throughout the process. We are realistic that we may not find a cure in Helen’s lifetime but we are hoping to help other people in some way. Also, by doing something positive and pro- active about it, is good for us both.” Helen began a clinical trial with Re:Cognition Health at their Centre in Guildford in December 2016.

An early diagnosis is essential to have a change to change your future.
10 early symptoms of cognitive impairment which may lead to dementia include:

  • Short term memory loss such as forgetting names and important dates and repeatedly asking the same questions
  • Changes in behaviour - unexpected & uncharacteristic anger and changes in mood, perhaps becoming passive and disinterested
  • Confusion which could include losing track of time or problems with processing information
  • Forgetting words and experiencing problems with speech and language
  • Loss of sense of direction, getting lost in a familiar environment and disorientated
  • Difficulty in performing everyday (seemingly normal) tasks such as making a cup of tea or unpacking the grocery shopping
  • Problems with calculation - managing money or completing simple sums and puzzles may become an issue
  • Misplacing items such as putting keys in freezer or milk in the dishwasher and not being able to retrace steps to find them
  • Difficulty making decisions which may also include making the wrong decision such as personal grooming
  • Issues with visual images and spacial awareness which may include difficulty reading words, judging distances or recognising colour contrast

Add new comment

By submitting this form, you accept the Mollom privacy policy.